GLP1R and cardiovascular disorder: The uptake of the glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors, classes of blood glucose-lowering therapies with glucose-independent benefits for cardiovascular disease, was relatively low in the FDS2 cohort (< 5% in each case at the end of the follow-up period) given that they were first introduced into Australia when the study was in progress.